Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversibly binding P2Y12 platelet inhibitor.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
* Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) and at least one additional risk factor for atherothrombotic events.
## Adult Dosing
* **ACS:**
* Loading Dose: 180 mg orally once.
* Maintenance Dose: 90 mg orally twice daily.
* **History of MI:** 60 mg orally twice daily.
* Dosing duration for ACS is typically 12 months, but may be extended based on individual patient risk and bleeding profile.
* For patients with a history of MI, continue therapy indefinitely as long as clinically indicated.
## Pediatric Dosing
Ticagrelor is not recommended for use in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is required for mild to moderate hepatic impairment. Caution advised in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is required for mild to moderate renal impairment. No specific recommendations for severe renal impairment are established, but caution is advised.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Common:** Dyspnea, bradycardia, ventricular pauses, increased risk of bleeding (major, minor, and fatal).
* **Serious:** Severe bleeding, anaphylaxis.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor exposure.
* **Other Antiplatelet Agents/Anticoagulants:** Concomitant use increases the risk of bleeding.
* **Digoxin:** Ticagrelor can increase digoxin levels. Monitor digoxin levels and adjust dose as needed.
* **Aspirin:** Coadministration with aspirin is recommended in ACS and post-MI patients, unless contraindicated.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor heart rate for bradycardia.
* Assess adherence and for potential drug interactions.
* Consider baseline and periodic assessment of renal and hepatic function.
## Clinical Pearls
* Ticagrelor is a reversibly binding P2Y12 inhibitor, which may be advantageous in patients who require a temporary cessation of therapy due to bleeding or planned surgery.
* Dyspnea is a common side effect and usually resolves without treatment discontinuation.
* Avoid concomitant use with prasugrel or clopidogrel.
* Dosing after PCI varies and may be guided by local protocols and specific stent therapy recommendations.
***
*This information is intended as a quick reference. Always consult the most current prescribing information and relevant clinical guidelines before making any therapeutic decisions.*
